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BACKGROUND AND OBJECTIVES: In Algeria, the incidence of hematologic malignancies has been difficult to 
estimate for many years. Today, many hematological centers, including 14 university hospitals, have been devel-
oped in the entire north and have useful epidemiological data pertinent to acute myeloid leukemia (AML). We 
studied the incidence of AML and its subtypes, age distribution, geographic distribution and trends in the rate 
of diagnosis over the last 5 years in Algeria. Secondary goals were to study trends of referral of AML cases from 
various regions to specific centers to assess the needs for health infrastructure and change of current practices.
DESIGN AND SETTING: Retrospective analysis of nationwide survey of all adult cases of AML (>16 years) diag-
nosed between 1 January 2006 and 31 December 2010. 
PATIENTS AND METHODS: A survey form was distributed to all departments of hematology at the 15 participat-
ing centers.
RESULTS: The 1426 cases of AML diagnosed during the study period represented an annual incidence of 
0.91/100 000 persons with a male to female (M/F) ratio of 1:16 and a median age of 45 years (range, 16-82 
years). Nationally, 20% of cases AML were diagnosed in the whole western region of the country, 47% in the 
central and 33% in the east. There was a trend of continuous increase in the rate with age and in the rate of 
diagnosis over the last 5 years. The most common subtype was M2, followed by M4 and M5.
CONCLUSION: An overall increase in the number of AML patients diagnosed nationwide over the last five 
years indicates a need for additional health care resources including curative and therapy-intense strategies, 
such as stem cell transplant facilities to optimize outcome. The relatively younger age of patients compared to 
the Western countries may be due to the demographic composition of our population.
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In Algeria, the incidence of various hematologic malignancies has been difficult to estimate for many years due to insufficient number of hema-
tological centers in a country covering an area of over 
two million square kilometers. Today, many hemato-
logical centers, including 14 university hospitals, that 
have been developed in the entire north, are reasonably 
distributed from east to west and have useful epide-
miological data pertinent to acute myeloid leukemia 
(AML). This has allowed better access of patients for 
earlier diagnosis and comprehensive care and better 
registration of valuable epidemiological data with sub-
sequent studies on many hematologic malignancies.1-5 
The national health system is based on free health 
care. Expenses are sponsored by a budget covered by 
the Ministry of Health and the social security office, 
and hematologic malignancies represent a significant 
part of this budget. In this context, an epidemiological 
study on AML in adults was conducted to determine 
its frequency and its clinical and financial impact, in 
order to assess the need for further development of 
institutional infrastructure or re-allocation of public 
health resources.
PATIENTS AND METHODS
We studied the incidence of adult AML, its subtypes, 
age and geographic distribution in Algeria and the 
trends in the rate of diagnosis over the last 5 years 
(from 1/1/2006 to 31/12/2010). Secondary goals in-
cluded the study of pattern of referral from various re-
gions to specific centers in order to assess the need for 
health infrastructure and change of current practices. 
A survey was distributed to all departments of hema-
tology at the 15 centers distributed across the coun-
try. These centers represent all the institutions where 
AML patients are referred (see list at end of article).
Patients were identified according to their age, sex, 
date of presentation and area of residency. All patients 
aged 16 years or older with de novo AML were includ-
ed. The diagnosis of AML was according to the World 
Health Organization (WHO) recommendations,6 af-
ter analysis of the blood smears, the bone marrow as-
piration, cytochemistry and flowcytometry for immu-
nophenotyping of blast cells. Subtypes of AML were 
grouped according to the French/American/British 
(FAB) group classification.7 Data on antecedent hema-
tological disorder or previous chemotherapy or radio-
therapy were not included.
 We estimated the overall median age for all patients 
and for each sex. We estimated crude incidence rates 
per 100 000 with 95% confidence intervals (95% CI). 
We also estimated incidence according to age at diag-
nosis, grouped into 7 categories: 16-20, 21-39, 40-49, 
50-59, 60-69, 70-79 and over 80 years. Statistical anal-
ysis was performed by the services of the Hematology 
and Cell Therapy and the services of Biostatistics of 
the 1st November E.H.U of Oran.
RESULTS
All the 15 hematological services of university hospi-
tals participated in this study, only the Establissement 
Public Hospitalier Mascara and the Department of 
Epidemiology and Biostatistics of the 1st November 
E.H.U Oran. All centers reported their data; there was 
a 100% response to the survey.
A total of 1426 adult patients (≥16 years of age) 
were diagnosed with AML from 1 January 2006 
through 31 December 2010 with a mean of 285.2 cases 
per year for the whole country, a mean of 19 cases per 
Table 1. Clinical characteristics of patients (n=1426) at diagnosis.
Median Range
Age (years) 44.7 16-82
Male 41.1
Female 44.6
White blood cell 
count (109/L) 150 8.9-285.0
Hemoglobin (g/dL) 7.5 3-9
Platelets (109/L) 2.5 0.1-24.0
Figure 1. Distribution by French-British-American classification.
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hematology service per year and 95 cases for the 5 years 
of the study period. There was a very wide variation 
in the rate among the centers (2.2 to 34.2 cases /year) 
with a median of 24 cases/year.
Table 1 shows clinical characteristics of patients 
at diagnosis. The overall median age was 44.7 years 
(41 years for males and 45 for females), with a slight 
predominance of males. Clinical presentation of AML 
at diagnosis was most often characterized by severe 
anemia, thrombocytopenia, and leukocytosis up to 
150.109/L. Of note was the presence of significant 
anemia in all of the patients (range of hemoglobin 3-9 
g/dL). The distribution according to FAB classifica-
tion showed a clear predominance of M2 type (36%), a 
low recruitment of M7 type (0.5%), while nearly 7% of 
cases were difficult to classify (Figure 1). Acute promy-
elocytic leukemia (APL) represented only 9.3%. Figure 
2 shows a trend of continuous annual increase in cases 
of AML where 246 cases had been registered in 2006, 
265 in 2007, 292 in 2008, 303 in 2009 and 320 in 
2010, with increase in the rate by 7.7%, 10.2%, 3.7% 
and 5.6%, respectively with a mean rate of increase of 
6.8% for the whole study period. The crude annual 
incidence per 100 000 of the population continued to 
rise from 0.7 in 2006 to 0.9 in 2010 (Figure 3). The 
age-specific incidence varied from 0.41 for ages 16- 20 
years, with a trend of a continuous increase in the rate, 
and a sharp increase to 2.65 after age 60 years reaching 
the highest 3.38 after age 80 (Figure 4). 
According to their place of care, the patient distri-
bution shows that over 70% had been diagnosed in the 
six oldest hematological centers in the country (Figure 
5), while according to their place of residence, the city 
of Algiers had the highest frequency of 12.9% (Figure 
6). Globally, 20% of AML were diagnosed in the whole 
western region of the country, 47% in the center and 
33% in the east (Figure 7).
DISCUSSION
To our knowledge, this is the first report that registers 
the trends in incidence of AML in Algeria and com-
pares incidence to that in Western countries. In this 
retrospective multicenter study, we identified 1426 
cases of AML over a period of five years (2006-2010) 
with the collaboration of all of hematology services 
across the country.
The cytological features showed a predominance 
of elevated white blood cell count at presentation as-
sociated with severe anemia and thrombocytopenia, 
which may reflect a delay in presentation or delay in 
referral. Although this may be rooted in a possible 
higher tolerance of patients to disease manifestation 
Figure 2. Annual number of acute myeloid leukemia cases.
with subsequent delay in seeking medical advice, it 
may also implicate intricate difficulties in accessing the 
relevant health care system and/or limited awareness. 
Nonetheless, such a delay may detrimentally affect the 
overall outcome.8
The proportions of the FAB classification types are 
substantially the same as that described in the literature, 
but with a very low rate of M7 (0.5% versus 1.5%), and 
more indeterminate forms (7% versus 1%).7 AML-M3 
represented only <10% of all cases, which is less than 
expected when considering the relatively younger me-
Figure 3. Annual incidence in cases per 100 000 population.
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dian age of our patient population (45 years). Such a 
phenomenon may be related to ethnic factors or to the 
natural history of APL which can present with a very 
acute course that should either be treated swiftly or 
patients die before they reach a tertiary care facility.9 
The marginal male predominance with a sex ratio of 
1.16 matches distributions in most countries.10
There was a clear trend of a steady increase in the 
annual frequency of AML during the study period 
which cannot be explainable by the expected yearly rise 
Figure 4. Age-specific incidence in cases of acute myeloid leukemia.
of the population census, but may be partly explained 
by an improvement in medical awareness, health care 
accessibility and recent expansion of health coverage. 
However, an actual increase of new cases related to the 
aging of the population and better diagnostics should 
also be considered.
The gross annual incidence per 100 000 people 
shows an increase from 0.7/100 000 in 2006 to 
0.91/100 000 in 2010, resulting in 314 new cases 
per year in a population of 34.1 million people.11 
However, such a rate is still low compared to that of 
Western countries, which is 3/100 000 inhabitants in 
France.12 In 2000–2003, the age-adjusted incidence 
rate of AML in the US was 3.7 per 100 000 for both 
sexes, 4.6 per 100 000 for males and 3.0 per 100 000 
for females.13 Further improvement in early diagnosis, 
early referral and collaborative work between primary 
care hospitals and the private sector of the health care 
system with tertiary care hematology centers should 
help in improving the rate of capturing such cases and 
proper referral for optimal management.
As expected, AML cases were clustered more dur-
ing later adulthood as seen universally. The annual 
incidence shows increasing age-specific rates from 
0.41/100 000 inhabitants before the age of 20 years 
to over six times the value (2.65/100 000 inhabitants) 
after 60 years and more than eight times the value 
(3.38/100 000 inhabitants) after 80 years. Such a 
trend has also been shown universally. The distribu-
tion of the proportion of prevalent cases of all leuke-
mias in the UK showed that 42.8% of patients are age 
>65 years with a median age of 65 years.14 From 2000 
to 2003, the US incidence rate in people aged <65 
years was only 1.8 per 100 000 persons, whereas the 
incidence rate in people aged over 65 years was 17 per 
100 000 persons.15 The relatively younger median age 
at diagnosis of AML in Algeria may reflect the rela-
tively younger population in comparison to the West.
Of note, there is a much younger age at presenta-
tion in Algeria, with an overall median age of 45 years 
versus 63 years in Europe14 and USA.15 This young 
age is found both in men (median age, 41 years) than 
in women (median age, 45 years) and is explained 
by the character of the young population of Algeria 
where more than half of Algerians are under 30 
years.16 Being young makes a large proportion of our 
patients eligible for curative intent with the plan of 
management including hematopoietic stem cell trans-
plant (HSCT). This may necessitate a change in prac-
tices to incorporate such a modality in the therapeutic 
package and should call for collaborative research tri-
als for high-risk patients who are not eligible for such 
Figure 5. Distribution of patients by center.
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Figure 6. Distribution by city.
a procedure. 
The distribution of patients in view of their place 
of care and of stay shows that the hematology depart-
ment of CPMC (the first and oldest hematology de-
partment in the country) is leading the recruitment of 
patients in Algiers, the capital city of Algeria, which 
is located on the Mediterranean Sea coast and may 
reflect the population density. The wide variation in 
recruiting patients between centers can be used in the 
future to allow center-to-center transfer of patients 
in case of capacity overflow. In addition, training pro-
grams to advance hematology subspecialties can be 
tailored and assigned to those centers with a larger pa-
tient load. The study also highlights the difference in 
distribution of patients in relation to demographics in 
the different regions of the country. The epidemiologi-
cal data identified the order of AML among other he-
matologic malignancies,17 occupying the top spot with 
acute lymphoblastic leukemia and highlights impor-
tant parameters like the annual incidence and the dis-
tribution of patients by health regions of the country. 
Such data helps organize the prioritization of existing 
resources, assess the needs, and calculate and planned 
expenditures on health infrastructure, especially con-
struction of new units for HSCT, and improves means 
of comprehensive diagnostics and treatment. The de-
velopment of HSCT, which was initiated in 1995 in 
Algiers, represents a great advancement in AML care. 
Algeria currently has two large HSCT units, CPMC 
Algiers, which can perform 120 allografts per year18,19 
and a second one that opened in May 2009 that serves 
those who need autologous transplants20,21 and hope-
fully will expand to add allografts in the near future. In 
2008-2009, 195 HSCT were reported from Algeria to 
the Eastern Mediterranean Bone Marrow Transplant 
(EMBMT) group and 64 (32.8%) were performed for 
AML (56 in first complete remission and 8 in second 
remission) making AML the most common single in-
dication for allogeneic HSCT in Algeria.22 However, 
this number represents only a small minority (<10%) 
of all AML cases registered in our current report for 
the same period 2008-2009 (total, 595). Because a 
much higher proportion of AML patients might need 
an allogeneic HSCT due to associated high-risk fea-
tures, the current situation creates a significant gap be-
tween the number of AML who are potential candidates 
for allogeneic HSCT and the actual number of AML 
patients receiving a transplant and should be considered 
in future planning to optimize patient outcome. HLA 
identical sibling donors may reach 70% in Algeria, mak-
ing allogeneic sibling transplant the preferred modality 
in such an aggressive disease when indicated.23 From 
Figure 7. Map of Algeria indicating geographic distribution of cases.
another perspective, this epidemiological study has al-
lowed us to show the very young character of our pa-
tients and indicates the need for serious thought to bet-
ter adapt new therapeutic strategies, particularly those 
used in children, which would be different from those 
used in Europe or the US.24
The Algerian Group for the Study of AML and my-
elodysplasia has been established to develop protocols 
for consensus in the diagnosis and management of he-
matologic malignancies, including AML. Further data 
collection related to the cytogenetic and molecular back-
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ground as well as treatment and outcome would greatly 
help in understanding this aggressive disease and refine 
long-term strategies to improve outcome.
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